Key Points
- Financial Lp Hrt acquired 72,912 Aditxt shares on April 21 at an average price of $0.33 (≈$24,060.96), raising its stake to 133,574 shares — a 120.19% increase.
- The same investor sold 11,982 shares on April 22 at an average price of $0.30 for about $3,594, with both transactions disclosed in an SEC filing.
- Aditxt shares opened at $0.29 and are trading lower, the stock carries a consensus "Sell" rating, and the company reports extreme negative profitability metrics and a micro market cap (~$260,460), signaling high financial and market risk.
Aditxt, Inc. (NASDAQ:ADTX - Get Free Report) major shareholder Financial Lp Hrt acquired 72,912 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The shares were bought at an average price of $0.33 per share, with a total value of $24,060.96. Following the transaction, the insider owned 133,574 shares in the company, valued at $44,079.42. This represents a 120.19% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Wednesday, April 22nd, Financial Lp Hrt sold 11,982 shares of Aditxt stock. The shares were sold at an average price of $0.30, for a total transaction of $3,594.60.
Aditxt Trading Down 6.6%
NASDAQ:ADTX opened at $0.29 on Friday. Aditxt, Inc. has a 12-month low of $0.28 and a 12-month high of $2,495.04. The firm has a market cap of $260,460.00, a price-to-earnings ratio of 0.00 and a beta of 1.74. The company's 50-day moving average is $2.04 and its two-hundred day moving average is $57.24.
Aditxt (NASDAQ:ADTX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $11,687.53 EPS for the quarter. Aditxt had a negative net margin of 1,217,927.00% and a negative return on equity of 374.60%.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Aditxt in a report on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Sell".
Read Our Latest Research Report on Aditxt
About Aditxt
(
Get Free Report)
Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt's approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.
The company's product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
